What Opella does

Opella is a global consumer healthcare company headquartered in Neuilly-sur-Seine, France, operating as the third-largest player in the worldwide over-the-counter (OTC) and vitamins, minerals, and supplements (VMS) market per Nicholas Hall's DB6 2024 ranking. The company was carved out from Sanofi and acquired by private equity firm Clayton, Dubilier & Rice in October 2025 for approximately $17.6 billion (€8 billion), becoming an independent entity with roughly 11,000 employees, 13 manufacturing sites, and 4 specialized R&D centers. Opella's portfolio spans approximately 100 consumer healthcare brands organized across five therapeutic clusters: allergy (Allegra, Xyzal, Telfast), pain and fever (Doliprane, Dorflex, Novalgina), digestive wellness (Dulcolax, Enterogermina, Essentiale, Buscopan, Maalox), respiratory (Mucosolvan, Bisolvon, Bronchicum, Nasacort, Maxilase), and men's health (Cialis), serving approximately 500 million consumers across 40+ countries.

The company generates revenue through branded OTC and VMS product sales distributed via a multi-channel architecture combining direct pharmacy relationships (the Opella+ platform connects 15,000+ pharmacies in France, with 40% placing orders through the platform), major retail partnerships (Amazon, Walmart), wholesale networks, and government healthcare channels (VA/DoD via Lovell). Pricing is unit-based across consumer healthcare SKUs (e.g., Dulcolax Daily Gut Support Gummies at $19.99 for a 60-count bottle). A strategic growth pillar involves executing Rx-to-OTC switches — most notably the Cialis OTC approval in Japan, Norway, and the UK — to expand consumer access to clinically proven treatments. The company also operates proprietary technology platforms including Opella+ for healthcare professionals and the Hyderabad Global Capability Centre (42,000 sq ft, up to 500 jobs) for operational scaling.

Opella's go-to-market blends enterprise field sales through pharmacy and HCP channels, channel partnerships with retail and pharmacy chains, and direct-to-consumer engagement via brand sponsorships (Andretti Global INDYCAR, Boston Marathon) and influencer campaigns. Disclosed 2024 revenues stand at approximately €5 billion, with strategic targets including training 200,000 pharmacists globally by 2030, reaching 50 million people annually through health literacy programs, and achieving B Corp recertification under the Health³ sustainability strategy. The company holds the distinction of being the first global consumer health company to achieve B Corp certification and has had its near- and long-term emissions targets validated by the Science Based Targets initiative (SBTi).

Name

Opella

Legal name

Opella Healthcare Group SAS

Website

https://opella.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

5,001–10,000 employees

Ownership category

akta.pro rank

Product category

Consumer Healthcare (OTC Pharmaceuticals & VMS)

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

OTC Pain Relief & Fever (Analgesics, Anti-inflammatory, Topical Pain Relief) (CRADAMAC)

akta.pro secondary industries

Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD), Gastrointestinal & Digestive Health (HLAIADAD), Allergy, Sinus & Respiratory (Non-Asthma) (HLAIADAC), Pain Relief & Anti-Inflammatory (Analgesics) (HLAIADAA)

Keywords

• Consumer healthcare
• OTC medications
• Vitamin supplements
• Pharmaceutical manufacturing
• Self-care products

Headquarters

HQ city

Neuilly-sur-seine

HQ country

France

HQ region

Europe

Offices5 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Marketing or Sales, Technology or R&D, Supply Chain, Infrastructure

Revenue model

1. OTC Pharmaceutical Products: Sale of over-the-counter medications including pain relief (Doliprane, Dorflex), allergy relief (Allegra, Xyzal), digestive health (Dulcolax, Essentiale, Enterogermina), and respiratory products (Mucosolvan, Bisolvon)
2. Vitamins, Minerals & Supplements (VMS): Sale of dietary supplements and wellness products across digestive health, bone health, and general wellness categories
3. Rx-to-OTC Switch Products: Revenue from transitioned prescription products (Cialis in Japan, Norway, UK) now sold over-the-counter through pharmacies

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Core offering

Opella manufactures and sells a portfolio of approximately 100 over-the-counter (OTC) medications, vitamins, minerals, and supplements (VMS) across allergy, pain, digestive, respiratory, liver, and men's health categories under brands such as Allegra, Doliprane, Dulcolax, Essentiale, Enterogermina, and Cialis. The company reaches over 500 million consumers globally through pharmacy networks, major retailers, and its Opella+ digital platform serving healthcare professionals.

Product overview

Opella is a global consumer healthcare company — the self-care challenger with the third-largest portfolio in the OTC & VMS market globally. The company operates as a portfolio of approximately 100 loved brands across core therapeutic categories: allergy (Allegra/Allervi, Telfast, Xyzal), pain and fever (Doliprane, Dorflex, Novalgina, Lysopaïne, Novanuit, Phytoxil), digestive wellness (Dulcolax, Enterogermina, Essentiale/FestalPro, Buscopan, Maalox), respiratory/mucus (Mucosolvan, Bisolvon, Bronchicum, Nasacort, Maxilase), and men's health (Cialis). The portfolio also includes Cortizone-10 for topical itch relief. The company also offers digital platforms including Opella+, a HCP-facing interface for pharmacists and general practitioners providing scientific content, training, and business management tools. Opella's open innovation pipeline covers 15 identified areas including disruptive liver care solutions, respiratory/nasal microbiota, constipation self-care, nighttime pain relief, next-gen natural bioactives, microbiome-based solutions, premium/innovative formats, biodegradable packaging, smart packaging, allergy prevention and self-treatment, dual-action constipation relief, abdominal pain treatment, next-gen magnesium solutions, cough relief, and reliable diagnostics. Manufacturing footprint includes 13 best-in-class manufacturing sites globally and 4 specialized science and innovation development centers.

Differentiator

Problem solved

Functional benefit

Brands

• Allegra: OTC allergy relief brand
• Buscopan
• Doliprane
• Dulcolax
• Enterogermina
• Essentiale
• Mucosolvan
• Xyzal
• Dorflex
• Novalgina
• Cortizone-10
• Maalox
• Bisolvon
• Cialis
• Telfast
• Bronchicum
• Nasacort
• Maxilase

Products and services

• Opella+ A unified digital interface for healthcare professionals (pharmacists and general practitioners) providing access to scientific content, training modules, decision-support tools, simplified accounting data access, optimised order management, and personalised support. Connects 15,000+ pharmacies in France with 40% placing orders via the platform.
• Allegra / Allervi Over-the-counter non-drowsy allergy relief medication sold globally. Allegra is the global brand name; Allervi is the French market brand name. Backed by a new granulation line at Compiègne, France for Allegra/Allervi production.
• Doliprane Pain relief and fever reducer brand widely available in several markets including France and Brazil. One of Opella's 100 loved consumer healthcare brands.
• Dulcolax Daily Gut Support Gummies Magnesium-based, stimulant-free daily supplement gummies for proactive gut health and digestive wellness. Available through Amazon, Walmart, and other select US retailers at a suggested retail price of $19.99 for a 60-count bottle.
• Dulcolax Laxative and digestive wellness brand. Recently expanded with Dulcolax Daily Gut Support Gummies marking entry into the proactive gut wellness market.
• Essentiale / FestalPro Essential phospholipid (EPL) liver health brand. Underpinned by the landmark EXCEL clinical study published in Liver International demonstrating 2.5x greater reduction in liver fat vs. diet and exercise alone in MASLD patients. Available globally including Hungary under the FestalPro trademark.
• Enterogermina Probiotic brand for digestive health, including paediatric use, supported by ongoing clinical and educational programs.
• Xyzal Over-the-counter allergy brand targeting nighttime allergy relief. Became first official allergy sponsor of the 2026 Boston Marathon.
• Buscopan Antispasmodic brand for abdominal pain and gastrointestinal discomfort relief, sold globally.
• Cialis Erectile dysfunction treatment brand. Successfully switched from prescription to OTC in Norway, UK, and Japan (June 2026). In Japan, classified as a 'Pharmacist-Intervention Required Medicine' with non-prescription approval granted to SSP Co., Ltd. (an Opella company).
• Cortizone-10 Topical anti-itch brand. Launched Itch Relief Cooling Spray through an 'Itchy Bear Season' campaign featuring influencer Dylan Efron, with a $475,000 donation to the National Park Foundation.
• Mucosolvan Respiratory/mucus relief brand sold globally.
• Maalox Antacid and digestive discomfort brand part of the gastrointestinal ecosystem alongside Enterogermina, Dulco, and Buscopan.
• Dorflex Pain relief brand available in Brazil, one of Opella's key brands in the third-largest market.
• Novalgina Pain and fever relief brand available in Brazil.

Quantifiable outcome

• 2.5 times greater reduction in liver fat vs diet and exercise alone (EXCEL clinical trial)
• +4 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability3 records

Feature2 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• LovellcoreStrategic or Co-development Partner · 29 April 2026Partnership aimed at increasing access to OTC healthcare products for the VA (Veterans Affairs) and DoD (Department of Defense) healthcare systems, expanding Opella's government healthcare market presence.
• NavancoreTechnology or Integration · 15 April 2026AI-powered business travel and expense management platform selected to manage Opella's global T&E program following its carve-out from Sanofi. Partnership targets up to 20% savings on annual travel spend, 95% platform adoption, and 96% traveler satisfaction. Covers both travel booking and expense management with end-to-end visibility.
• Global Self-Care FederationcoreStrategic or Co-development Partner · 24 March 2026Josephine Fubara, Chief Science Officer at Opella, unanimously elected as Chair Elect of GSCF, which is focused on positioning self-care as cornerstone of Universal Health Coverage and sustainable health systems globally.
• Long Chau PharmacyminorGTM or Marketing Partner · 1 February 2026Vietnam pharmacy partnership for digestive and bone health awareness collaboration, part of Opella's market expansion in Asia Pacific region.
• Men's Health ForumminorStrategic or Co-development PartnerUK men's health charity supported by Opella for research on pharmacy engagement. Report 'An Unfilled Prescription' highlights opportunity for UK pharmacies to advance men's health with 92% of men using local pharmacies but 74% never discussing health with pharmacists.
• International Pharmaceutical Federation (FIP)coreStrategic or Co-development PartnerIndustry partnership supporting the front lines of self-care as part of Opella's health literacy mission. FIP collaboration for pharmacist training targeting 200,000 pharmacists by 2030.
• Forum for the Future's Climate Health CoalitionminorStrategic or Co-development PartnerWorking at the intersection of climate impact and health as part of Opella's sustainability and social impact initiatives.
• SIFAC (Società Italiana Farmacia Clinica)minorStrategic or Co-development Partner'Capire la Pancia' project developed with Italian clinical pharmacy society to improve management of gastrointestinal disorders and strengthen pharmacy's role in self-care, targeting 20,000 pharmacists nationwide.
• EASL (European Association for the Study of the Liver)coreStrategic or Co-development PartnerSLD Summit host for satellite symposiums on MASLD/fatty liver disease. Opella presented EXCEL clinical trial findings and launched 'The Fatty Liver Constellation' capability building program at EASL Congress 2026.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Reckitt Benckiser (Health): Reckitt's Health division (Gaviscon, Nurofen, Mucinex, Durex, Strepsils) is a major OTC competitor operating within a broader consumer goods conglomerate. It overlaps with Opella in digestive, pain, and respiratory categories and is also a talent competitor.
• Bayer Consumer Health: Bayer's Consumer Health division (Aspirin, Claritin, Aleve) is a global OTC peer but operates as part of the broader Bayer conglomerate. It overlaps with Opella in pain and allergy categories and competes for shelf space in Europe and the Americas.

Direct peers

• Kenvue: Kenvue is the consumer health spin-off of Johnson & Johnson (Tylenol, Zyrtec, Motrin, Band-Aid, Neutrogena). It directly competes with Opella in OTC pain, allergy, and digestive categories with a similar mass-market retail and pharmacy channel mix.
• Haleon: Haleon is the largest pure-play OTC & consumer health company globally (Sensodyne, Advil, Centrum, Panadol), formed from the GSK Consumer Healthcare spin-off. It is the most direct comparable to Opella in product mix, geographic footprint, and pharmacy-led GTM motion.
• Perrigo Company: Perrigo is a leading global OTC and self-care company focused on store-brand/private-label and specialty pharmaceuticals. It directly competes with Opella in digestive, allergy, and pain categories, particularly through private-label alternatives in Europe and the US.
• Prestige Consumer Healthcare: Prestige Consumer Healthcare is a US-focused OTC company (Claritin, BC/Goody's, Monistat) with a similar strategy of acquiring and revitalizing heritage OTC brands. It is directly comparable to Opella in brand-portfolio management and US market execution.

Regional players

• Hyphens Pharma: Hyphens Pharma is a Singapore-headquartered consumer health and pharmaceutical company serving ASEAN markets. It is comparable to Opella's emerging-market expansion model, particularly the Vietnam and ASEAN pharmacy partnerships.
• Taisho Pharmaceutical: Taisho Pharmaceutical is a major Japanese OTC and consumer health company (Lipovitan, RiUP). It is a regional peer that operates in Opella's key Japan Rx-to-OTC market and shares expertise in pharmacist-channel GTM models in Asia.
• Dabur India: Dabur is a leading India and South Asia consumer healthcare and Ayurvedic OTC company (Dabur Honitus, Pudin Hara). It is a regional OTC peer relevant to Opella's emerging-market expansion strategy, particularly India where Opella is building its Hyderabad GCC.

Emerging players

• Church & Dwight: Church & Dwight (Batiste, OxiClean, Trojan) is increasingly active in OTC and personal care adjacencies with selective OTC plays. It is comparable to Opella as a brand-driven consumer health operator with M&A-led growth discipline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/Opella
• YouTubeyoutube.com/@Opella
• Facebookfacebook.com/Opella
• LinkedInlinkedin.com/company/opella-health
• Instagraminstagram.com/opella
• TikToktiktok.com/@opella

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries18 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Opella